On September 22, Pfizer announced on its official WeChat account that its phase II clinical trial of the monoclonal antibody Ponsegromab targeting growth differentiation factor-15 (GDF-15) had reached the primary endpoint, which was a significant change in weight compared to baseline in cancer cachexia and GDF-15 elevation patients treated with Ponsegromab compared to placebo. Malignancy is a common and life-threatening debilitating disease that can seriously affect the quality of life of cancer patients. Based on these positive results, Pfizer is in discussions with regulatory agencies regarding future development plans, with the goal of initiating registration studies by 2025. The phase II clinical study of Ponsegromab in patients with heart failure (HF) and elevated serum GDF-15 concentration (NCT05492500) is currently underway.